What is Endogenex?
Endogenex is a medical technology firm dedicated to redefining the standard of care for type 2 diabetes. The company utilizes a specialized endoscopic catheter to deliver non-thermal pulsed electric fields (PEF) to the mucosa and sub-mucosa of the duodenum. This procedure is designed to initiate the body's natural cell regeneration processes, effectively treating the inflamed and dysfunctional tissue associated with diabetic duodenopathy. By focusing on the gut as a primary driver of metabolic health, Endogenex aims to provide a transformative, outpatient alternative to chronic pharmaceutical reliance, potentially slowing or halting the progression of the disease. The company's market position is defined by its unique intersection of gastroenterology and metabolic science, offering a high-barrier-to-entry solution in the competitive landscape of diabetes care.
How much funding has Endogenex raised?
Endogenex has raised a total of $190.3M across 4 funding rounds:
Series A
$34M
Series B
$18.3M
Series C
$88M
Series C
$50M
Series A (2023): $34M with participation from Longitude Capital
Series B (2023): $18.3M, investors not publicly disclosed
Series C (2024): $88M supported by Hatteras Venture Partners and Lumira Ventures
Series C (2026): $50M featuring Arboretum Ventures
Key Investors in Endogenex
Arboretum Ventures
Arboretum Ventures is a Midwest-based healthcare venture capital firm with over 20 years of experience in investing in innovative healthcare solutions, focusing on early-stage startups in under-ventured markets.
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors, providing both capital and strategic support.
Lumira Ventures
Lumira Ventures is Canada's largest life sciences venture capital firm, specializing in investments in healthcare innovators across various stages, from early-stage to revenue-generating biotech and medical devices.
What's next for Endogenex?
With the successful closure of this latest financing, Endogenex is poised to accelerate its clinical development roadmap. The strategic focus will likely center on expanding multi-center clinical trials to further validate the efficacy and safety of its PEF-based endoscopic procedure. As the company moves toward regulatory milestones, the infusion of capital will support the scaling of manufacturing capabilities and the expansion of its commercial infrastructure. Investors are closely watching the company's ability to translate its innovative science into a scalable, standard-of-care procedure that could fundamentally alter the treatment paradigm for millions of patients suffering from type 2 diabetes. Future growth will be contingent upon successful data readouts and the continued support of its syndicate of specialized healthcare investors.
See full Endogenex company page
